USPTO Biotech/Chemical Partnership (BCP) Meetings

May 7, 2019, 18:32 PM by AIPLA Admin

Summary: BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality of the agency’s products and services. The next meeting’s discussion topics include: Subject Matter Eligibility (35 U.S.C. §101) 2019 Patent Subject Matter Eligibility Guidance Update; Stakeholder Perspectives on 101; Subject Matter Eligibility Discussion Panel; Written Description TC1600 Quality Initiatives and Plans; Global Dossier; Cooperative Patent Classification in Biotech.

Global Biotechnology/Chemical/Pharmaceutical Customer Partnership 
Wednesday, May 8, 2019 
9 a.m. to 4 p.m. ET 
United States Patent and Trademark Office 
East Coast: USPTO Alexandria Campus, Madison Auditorium, North 
Midwest Region: Midwest Regional Office, Detroit

Share your insights and experiences to improve patent prosecution in biotechnology areas at the USPTO’s next Biotechnology, Chemical and Pharmaceutical Customer Partnership (BCP) Meeting. The meeting will be held simultaneously at the USPTO headquarters in Alexandria, Virginia, and the Midwest Regional Office in Detroit, Michigan, and online. Participants will be able to speak with agency experts either in person or via webcast from all locations.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality of the agency’s products and services. The next meeting’s discussion topics include:

• Subject Matter Eligibility (35 U.S.C. §101) 2019 Patent Subject Matter Eligibility Guidance Update
• Stakeholder Perspectives on 101
• Subject Matter Eligibility Discussion Panel
• Written Description
• TC1600 Quality Initiatives and Plans
• Global Dossier
• Cooperative Patent Classification in Biotech

2019 PEG 101 Slides

1. BCP Agenda-Final-All approved
2. CPCforBCP-approved
3. Patents Ops-Quality Action Plan for BCP 1600-Final-approved
4. Antibody WD-BCP 1600 May 2019 Final Approved
   
   9 – 9:20 a.m.
   Welcoming and opening remarks
   Damian Porcari Director, Midwest Regional Office, USPTO
   Andrew Wang Director, TC 1600, USPTO (in person @Detroit)
   Gary Jones Director, TC 1600, USPTO (in person @Alexandria)
   Daniel Sullivan Director, TC 1600, USPTO (in person @Alexandria)
   
   9:20 – 9:50 a.m.
   TC quality action plan
   Anne Gussow QAS, TC 1600, USPTO (in person @Detroit) 
   
   9:50 – 10:30 a.m.
   Antibody decisions and the written description requirement
   Lora Driscoll, QAS, TC 1600, USPTO (@Alexandria) 
   
   10:40 – 11:30 p.m.
   Subject matter eligibility (35 U.S.C. §101)-2019 patent subject matter eligibility guidance (PEG) update
   Marjorie Moran, SPE, TC 1600, USPTO (@Alexandria)
   
   12:30 – 1:20 p.m.
   Subject matter eligibility (101) outside perspectives
   Kathleen E. Chaffee, Patent Agent, Office of Technology Management, Washington University (@Detroit) 
   
   1:20 – 2:50 p.m.
   101 discussion panel
   Moderator: Andrew Wang, Director, TC 1600, USPTO
   Panelists:
   Beverly A. Lyman, Chief Intellectual Property Counsel, Indiana University (@Detroit)
   Duane C. Marks, Patent Counsel, Bio-Products Eli Lilly and Company (@Detroit)
   June Cohan, Senior Legal Advisor, OPLA (@Alexandria)
   Marjorie Moran, SPE, TC 1600, USPTO 
   
   3:00 – 3:30 p.m.
   Global Dossier
   Nelson Yang, Acting Director, IPBS, OIPC, USPTO (@Alexandria) 
   
   3:30 – 3:50 p.m.
   Cooperative Patent Classification (CPC) application in biotechnology
   Melenie Gordon; Sue Liu SPEs, TC 1600, USPTO (@Alexandria) 
   
   3:50 – 4:00 p.m. Closing remarks TC Directors